4.2 Article

Daily low dose intravesical cidofovir for the treatment of BK virus associated hemorrhagic cystitis after allogeneic stem cell transplantation

Related references

Note: Only part of the references are listed.
Article Immunology

Risk factors of BK viral hemorrhagic cystitis in allogenic hematopoietic stem cell transplantation

Eleonore Kaphan et al.

Summary: Exposure to cyclophosphamide, younger age (<40), and corticosteroid therapy are potential risk factors for developing BKV-HC.

TRANSPLANT INFECTIOUS DISEASE (2021)

Review Infectious Diseases

Review of Intravesicular Cidofovir for BK Virus Hemorrhagic Cystitis

Danica Palacio et al.

Summary: Intravesicular cidofovir treatment for BKV-induced hemorrhagic cystitis has shown promising results with minimal reported toxicity. However, further randomized controlled trials are needed to confirm its efficacy.

CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES (2021)

Review Urology & Nephrology

The 6R's of drug induced nephrotoxicity

Linda Awdishu et al.

BMC NEPHROLOGY (2017)

Article Infectious Diseases

Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients

Samuel L. Aitken et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)

Letter Hematology

Intravesicular Cidofovir for the Management of BK Virus-Associated Cystitis

Kamakshi V. Rao et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)

Review Infectious Diseases

Polyomavirus BK

HH Hirsch et al.

LANCET INFECTIOUS DISEASES (2003)